Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

Bone Reports

Volumn 5, Issue , 2016, Pages 158-162

  Ruppe, Mary D ^a   Zhang, Xiaoping ^b   Imel, Erik A ^c   Weber, Thomas J ^d   Klausner, Mark A ^b   Ito, Takahiro ^b   Vergeire, Maria ^b   Humphrey, Jeffrey S ^b   Glorieux, Francis H ^e   Portale, Anthony A ^f   Insogna, Karl ^g   Peacock, Munro ^c   Carpenter, Thomas O ^g  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibroblast growth factor 23 (FGF23); Health related quality of life; KRN23; Rickets; X linked hypophosphatemia

Indexed keywords

BUROSUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE ESCALATION; EMOTIONAL STABILITY; HUMAN; MENTAL HEALTH; MULTICENTER STUDY; OPEN STUDY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN; PERCEPTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SOCIAL INTERACTION; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; X LINKED HYPOPHOSPHATEMIC RICKETS;

EID: 84973163800     PISSN: None     EISSN: 23521872     Source Type: Journal    
DOI: 10.1016/j.bonr.2016.05.004     Document Type: Article

References (28)

1. Imel E.A., Econs M.J. Fibroblast growth factor 23: roles in health and disease. J. Am. Soc. Nephrol. 2005, 16:2565-2575.
2. Liu S., Quarles L.D. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 2007, 18:1637-1647.
3. Carpenter T., Imel E.A., Holm I.A., et al. A clinician's guide to X-linked hypophosphatemia. J. Bone Miner. Res. 2011, 26:1381-1388.
4. Lee J.Y., Imel E.A. The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr. Endocrinol. Rev. 2013, 10(Suppl. 2):367-379.
5. Holm I.A., Econs M.J., Carpenter T.O. Familial hypophosphatemia and related disorders. Pediatric Bone: Biology & Diseases 2003, 603-631. Academic Press, San Diego. F.H. Glorieux, H. Juppner, J.M. Pettifor (Eds.).
6. Reid I.R., Hardy D.C., Murphy W.A., et al. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore) 1989, 68:336-352.
7. Tenenhouse H.S., Econs N.J. Mendelian hypophosphatemia. The online metabolic and molecular bases of inherited diseases (OMMBID); Part 21 (Chap. 197) 2013, (http://www.ommbid.com/OMMBID/the_online_metabolic_and_molecular_bases_of_inherited_disease/b/abstract/part21/ch197. Accessed 1 October 2013).
8. Costa T., Marie P.J., Scriver C.R., et al. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J. Clin. Endocrinol. Metab. 1981, 52:463-472.
9. Carpenter T.O., Imel E.A., Ruppe M.D., et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Investig. 2014, 124:1587-1597.
10. Imel E.A., Zhang X., Ruppe M.D., et al. Prolonged correction of serum posphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J. Clin. Endocrinol. Metab. 2015, 100(7):2565-2573.
11. Maruish M.E. User's manual for the SF-36v2 health survey 2011, QualityMetric Inc., Lincoln, (RI.7 March 2016). third ed.
12. Bellamy N., Buchanan W.W., Goldsmith C.H., et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 1988, 15:1833-1840.
13. Bellamy N. WOMAC Osteoarthritis Index User Guide IX 2009, University of Queensland, Brisbane, Australia.
14. Bellamy N. WOMAC Osteoarthritis Index LK3.1 (IK) 2004, (http://www.fizjoterapeutom.pl/attachments/article/348/2008-4404b1-05-WOMAC-Questionnaire.pdf. (Accessed on April 9, 2016)).
15. Bellamy N., Wilson C., Hendrikz J. Population-based normative values for the Western Ontario and McMaster (WOMAC) Osteoarthritis Index: part I. Semin. Arthritis Rheum. 2011, 41(2):139-148.
16. Hommel G.A. Comparison of two modified Bonferroni procedures. Biometrika 1988, 75:383-386.
17. Nunnally J.C. Psychometric Theory 1978, McGraw-Hill, New York. second ed.
18. Sullivan W., Carpenter T., Glorieux F., et al. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 1992, 75:879-885.
19. i-IIC in maintaining phosphate homeostasis. Am. J. Hum. Genet. 2006, 78:179-192.
20. Schott G.D., Wills M.R. Muscle weakness in osteomalacia. Lancet 1976, 1:626-629.
21. Bellamy N. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J. Rheumatol. 2002, 29:2473-2476.
22. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford) 1999, 38:355-361.
23. Ware J.E., Kosinski M. SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1 2001, QualityMetric, Lincoln, RI. second ed.
24. Veilleux L.N., Cheung M., Ben Amor M., et al. Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 2012, 97:E1492-E1498.
25. Veilleux L.N., Cheung M.S., Glorieux F.H., et al. The muscle-bone relationship in X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 2013, 98:E990-E995.
26. Knochel J.P. Neuromuscular manifestations of electrolyte disorders. Am. J. Med. 1982, 72:521-535.
27. Land J.M., Kemp G.J., Taylor D.J., et al. Oral phosphate supplements reverse skeletal muscle abnormalities in a case of chronic fatigue with idiopathic renal hypophosphatemia. Neuromuscul. Disord. 1993, 3:223-225.
28. Ambühl P.M., Meier D., Wolf B., et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am. J. Kidney Dis. 1999, 34:875-883.